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Devices in Heart Failure
Potential Methods for Device-Based  
Monitoring of Congestive Heart Failure
Congestive heart failure has long been one of the most serious medical conditions in 
the United States; in fact, in the United States alone, heart failure accounts for 6.5 mil-
lion days of hospitalization each year. One important goal of heart-failure therapy is to in-
hibit the progression of congestive heart failure through pharmacologic and device-based 
therapies. Therefore, there have been efforts to develop device-based therapies aimed at 
improving cardiac reserve and optimizing pump function to meet metabolic requirements. 
The course of congestive heart failure is often worsened by other conditions, including 
new-onset arrhythmias, ischemia and infarction, valvulopathy, decompensation, end- 
organ damage, and therapeutic refractoriness, that have an impact on outcomes. The onset 
of such conditions is sometimes heralded by subtle pathophysiologic changes, and the 
timely identification of these changes may promote the use of preventive measures. Con-
sequently, device-based methods could in the future have an important role in the timely 
identification of the subtle pathophysiologic changes associated with congestive heart fail-
ure. (Tex Heart Inst J 2008;35(2):166-73)
ongestive heart failure (CHF), long one of the nation’s most serious medical 
problems, contributes to approximately 250,000 deaths each year. About 2% 
of the total population has CHF, and it accounts for about $20 billion an-
nually in health-care expenses. In the United States alone, heart failure accounts for 
6.5 million days of hospitalization annually.1,2 The mean length of hospital stay for a 
CHF-related admission is approximately 14 days.1
 One important goal of heart-failure therapy is to inhibit the progression of CHF 
through pharmacologic and device-based therapies. Accordingly, there have been in-
tensive efforts to develop device-based therapies aimed at improving cardiac reserve 
and optimizing pump function to meet metabolic requirements. The fairly indolent 
course of CHF is often worsened by overriding perturbations, including new-onset ar-
rhythmias, ischemia and infarction, valvulopathy, decompensation, end-organ dam-
age, and therapeutic refractoriness, which have an impact on outcomes. For example, 
mortality rates are 34% higher in CHF patients who have atrial fibrillation than in 
patients who have CHF alone.3
 The onset of conditions known to worsen patients’ prognoses is sometimes herald-
ed by subtle pathophysiologic changes. The timely identification of such changes can 
enable preventive measures, and device-based methods should have an important role 
in this process.
 The purpose of the present review is to survey the pathophysiologic processes that 
can now be monitored by mechanical devices and to provide information about pre-
dicting the onset of a condition that can aggravate CHF. In the interest of brevity (in 
dealing with a vast subject), we will discuss only those select pathologic conditions 
that occur frequently in CHF patients and adversely affect outcomes. Table I provides 
a summary of devices and procedures that have the potential of predicting these ad-
verse events.
New-Onset Atrial Fibrillation
Atrial fibrillation (AF) and CHF tend to coexist, and the prevalence of AF increas-
es in parallel with the severity of CHF.4 Atrial fibrillation may affect as few as 5% of 
CHF patients with mild disease3 and as many as 50% with New York Heart Associ-
ation (NYHA) functional class IV symptoms.5 In a study of 1,470 Framingham par-
ticipants who developed AF, CHF, or both, 382 (26%) developed both, and 41% 
of that number had CHF first.6 These statistics correlate with reports of AF preva-
lence published elsewhere.7 Although some studies have shown variability in the asso-
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ciation between AF and increased death, other studies 
have shown that AF plays an important role in predict-
ing death.8,9 The impact of AF on CHF death (Fig. 1) 
is particularly significant if the CHF is mild10 or if car-
diac decompensation is present.11
 The development of AF in CHF patients can be ex-
plained by impaired hemodynamics, an altered neu-
rohumoral state, and an acute rise in atrial pressure, 
all of which promote electrical and structural remod-
eling and elicit mechanoelectrical feedback within the 
TABLE I. Devices in Heart Failure
               Condition Device or Procedure How Future Events Are Predicted
Atrial fibrillation Periodic 2D echocardiography Measures increased atrial diameter (>40 mm), 
     low left ventricular fractional shortening, left 
     ventricular wall thickness
Right ventricular dysfunction Periodic 2D echocardiography Measures RVWT ≥0.8 mm, RVEDD >6 mm,  
     TAPSE <1.6 mm, PAAT/CL ratio <0.08
Nonischemic cardiomyopathy Electrical impedance spectroscopy Measures changes in myocardial resistance 
     secondary to ischemia
 Intracardiac electrocardiography Measures changes in myocardial resistance 
     secondary to ischemia
CAD/ischemia Peak endocardial acceleration Measures changes in myocardial resistance 
     secondary to ischemia
 Coronary sinus thermometry May show increased coronary sinus tempera-  
     ture with ischemic/obstructive CAD
 Ballistocardiography Noninvasively records the stroke volume of the  
     heart for calculating cardiac output
 Seismocardiography Noninvasively records cardiac vibrations and 
     measures acute and chronic changes in left 
     ventricular function
 Strain-rate imaging Measures the timing and extent of myocardial 
     deformation and provides more reliable 
     information about the sequence of myocardial 
     contraction in the presence of delayed  
     electrical activation
Cardiac decompensation Noninvasive impedance cardiography Measures TFC and changes in thoracic electrical 
     impedance as a consequence of TFC
 OptiVol Monitors thoracic impedance through biventric- 
     ular pacemaker electrodes and gives a general  
     indication of the fluid balance of patients; help- 
     ful in predicting impending volume overload
 HeartPOD Measures left atrial pressures and provides an 
     indirect estimate of PCWP in impending 
     decompensation
 Hypothermia May serve as a univariate predictor of in-hospital 
     death in patients with CHF decompensation  
     and may also serve to predict CHF  
     decompensation
 Chronicle Measures right ventricular pressures and  
     estimated pulmonary artery diastolic pressure  
     through a lead implanted in the right ventricu- 
     lar outflow tract
Sudden cardiac death Implantable defibrillators Primary and secondary prevention
 Signal-averaged electrocardiography Risk stratification
 T-wave alternans Risk stratification
 Heart rate variability Risk stratification
 
CAD = coronary artery disease; CHF = congestive heart failure; PAAT/CL = pulmonary artery acceleration time/cycle length; 
PCWP = pulmonary capillary wedge pressure; RVEDD = right ventricular end-diastolic dimension; RVWT = right ventricular 
free-wall thickness; SCD = sudden cardiac death; TAPSE = tricuspid excursion; TFC = thoracic fluid content; 2-D = 2-dimen-
sional
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atria.12,13 Structural remodeling, including fibrosis and 
dilatation, is, at some level, mediated by humoral fac-
tors such as angiotensin.10 Potent profibrotic molecules 
such as angiotensin II, which circulate abundantly in 
the bloodstreams of CHF patients, promote the disper-
sion of atrial impulse conduction and re-entry by alter-
ing the atrial ultrastructure.14
 In a prospective study conducted in Framingham 
participants to determine which impaired mechanics 
of cardiac activity lead to AF, an analysis of echocar-
diographic data showed that increased atrial diameter, 
increased left ventricular wall thickness, and low left ven-
tricular fractional shortening were predictive of AF.15 
The study’s conclusions, however, were reached on the 
basis of periodic echocardiographic measurements and 
lacked information on serial changes in the described 
echocardiographic values. Therefore, the study was in-
conclusive in describing rates of change and cut-off 
points in the echocardiographic measurements of in-
terest. However, others have shown that left atrial di-
ameters >40 mm are indeed associated with increased 
risk of AF.16
 It should be noted that cardiac biometry varies with 
an individual’s height; therefore, in clinical practice, 
it may not be feasible to apply cut-off points. Rates of 
change in variables that one predictive of future AF 
may be a more effective indication and afford a better 
standard. Measurement of such variables and their rates 
of change could be achieved with continuous monitor-
ing devices, which could prove useful in the early iden-
tification of high-risk patients.
New-Onset Right Ventricular Dysfunction
Right ventricular dysfunction may constitute the “com-
mon final pathway” in the progression of CHF.17 How-
ever, there are no clear data to describe the epidemiology 
and pathophysiology of right ventricular dysfunction 
and how it complicates the prognoses of patients with 
pre-existing left ventricular dysfunction. Inferences can 
be made from studies that recruited patients with iso-
lated left ventricular dysfunction, in whom right ven-
tricular dysfunction could develop as their disease 
progressed.18 The anatomically united ventricles exhibit 
mechanical coupling, in which the performance of one 
ventricle has an effect on the other. This mechanical in-
terdependence is another means by which a pathologic 
process can be diffused.19,20
 A study by Mariano-Goulart and associates21 deter-
mined that there is a correlation between high levels 
of brain natriuretic peptide and right ventricular dys-
function. That study compared plasma brain natriure-
tic peptide (BNP) levels in patients who had isolated 
left ventricular dysfunction with levels in patients who 
had biventricular dysfunction and found that right-sid-
ed heart failure contributed substantially to the eleva-
tion of BNP. The authors concluded that important 
BNP increases in patients with “isolated” left ventricular 
dysfunction should indicate a high risk of right ventric-
ular dysfunction. From the results of another study, by 
Ahmed and colleagues,22 it may be inferred that approx-
imately 35% of CHF patients have isolated left ventric-
ular dysfunction. Therefore, a fairly large population of 
patients with lone left-sided failure may eventually de-
velop right ventricular dysfunction during the course of 
their disease.
 Other studies of the prognostic impact of right ven-
tricular dysfunction reveal its importance in predicting 
functional capacity and short-term outcomes in CHF 
patients.23-27 In a prospective study of the role of right 
ventricular ejection fraction (RVEF) in predicting short-
term outcomes in 142 ambulatory patients who were 
awaiting cardiac transplantation, an RVEF <24% was 
found to be predictive of a greater death rate.28 In addi-
tion, survival and symptoms are worse in patients with 
dilated cardiomyopathy and biventricular failure than 
in patients whose RVEF is close to normal (>35%).25 
In another study, RVEF together with NYHA classifi-
cation and functional capacity were predictive of surviv-
al in patients with mild-to-moderate CHF symptoms.23 
Right ventricular function remains important in pre-
dicting functional capacity and short-term outcomes, 
particularly in very ill patients for whom the left ventric-
ular ejection fraction (LVEF) is not as reliable for pre-
dicting those same outcomes (Fig. 2). The evaluation of 
right ventricular systolic and diastolic function provides 
complementary information, with a very high power to 
stratify the prognoses of patients with heart failure.26
 Despite its powerful prognostic implications, the right 
ventricle is not as well studied as the left.17 Data on right 
ventricular pathophysiology have been drawn from an-
imal models of right ventricular dysfunction. Hardzi-
yenka and coworkers24 studied the progressive changes 
in selected echocardiographic variables that preceded 
Fig. 1  New-onset atrial fibrillation is associated with increased 
risk of death in congestive heart failure. (Reprinted with permis-
sion from Swedberg K, Olsson LG, Charlesworth A, Cleland 
J, Hanrath P, Komajda M, et al. Prognostic relevance of atrial 
fibrillation in patients with chronic heart failure on long-term treat-
ment with beta-blockers: results from comet. Eur Heart J 2005; 
26[13]:1303-8.)
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right-sided heart failure in rats. All variables deteriorated 
progressively: right ventricular free-wall thickness, ≥0.8 
mm; right ventricular end-diastolic diameter, >6 mm; 
tricuspid excursion, <1.6 mm; and pulmonary artery 
acceleration time normalized to cycle length (PAAT/
CL ratio), <0.08. Interestingly, the deterioration pre-
ceded the development of overt right-sided heart failure 
and followed a distinct temporal sequence. The investi-
gators concluded that these variables were useful in pre-
dicting the onset of right ventricular failure in rats and 
that their applicability to human beings should be in-
vestigated.24
 These methods and variables may be used for device-
based monitoring that could facilitate the prediction of 
right ventricular dysfunction before the onset of overt 
right-sided heart failure in patients with pre-existing dis-
ease.
New-Onset Ischemia in  
Nonischemic Congestive Heart Failure
There is a distinct paucity of data on the incidence of 
new-onset coronary artery disease in patients who al-
ready have a diagnosis of nonischemic CHF. Coronary 
artery disease (CAD) is a real and possibly under-recog-
nized phenomenon in nonischemic CHF. For heart-
failure patients in whom the ischemic portion of the 
disease has escaped notice, there is risk of future isch-
emia and infarction. The risks of ischemic complica-
tions in these patients and the affect on outcomes are 
unknown,29 as is the contribution of CHF to atherogen-
esis and CAD. Vague estimates of the incidence of isch-
emia and infarction in nonischemic CHF patients may 
be made on the basis of data available from some clinical 
trials.30,31 However, these estimates have inherent limi-
tations—mainly that the diagnostic methods used in 
classifying CHF populations into ischemic and nonis-
chemic subgroups yield high numbers of false positives 
for ischemia.32 In addition, an ischemic episode can ap-
pear to be sudden cardiac death (SCD) in the already-
weakened heart. In such cases, a diagnosis is made only 
at autopsy, which is not routinely performed. In a search 
of the medical literature, we found no studies other than 
clinical trials that provided data on the epidemiology of 
new-onset CAD in nonischemic CHF patients. The 
manifestation rate of CAD averaged 7% to 12% per le-
sion per year.33,34
 Although devices that detect electrical and mechani-
cal changes in the heart may show the presence of isch-
emia, there are other potential detection methods for 
use in implantable devices. Electrical impedance spec-
troscopy, for example, measures changes in myocardial 
resistance that are secondary to ischemia. This method 
has been used in the diagnosis of several diseases, in-
cluding breast cancer, cervical cancer, and tumors of the 
urothelium, in addition to myocardial ischemia.35 Repo-
larization abnormalities are also often used for diagnos-
ing ischemia, and these changes are measurable through 
intracardiac and intracoronary approaches. Intracardiac 
electrocardiography (ECG) has been found to be more 
sensitive than surface ECG and to show ischemic re-
sponses earlier, even in the presence of intraventricu-
lar conduction delays (for example, left bundle-branch 
block).36 Electrocardiography performed with electrodes 
placed within the coronary arteries also provides in-
creased sensitivity and specificity.37 Other methods of 
detecting ischemia include peak endocardial accelera-
tion measurement, coronary sinus thermometry, bal-
listocardiography, seismocardiography, and strain-rate 
imaging.38-42
 Guidelines for the clinical monitoring of CAD are 
well defined in the medical literature. At the same time, 
considerable work is being done to decrease morbidity 
and death associated with ischemia. Real-time, device-
based monitoring, although not routinely used, may be 
beneficial in high-risk patients, particularly those whose 
hearts are already compromised and least able to sustain 
a superimposed myocardial insult.
Decompensation
Cardiac decompensation is a “period of broken com-
pensation” associated with “embarrassed circulation”43 
and characterized by reduced cardiac output, hypo-
perfusion, tissue congestion, and an increased pulmo-
nary capillary wedge pressure. Numerous precipitating 
factors may worsen cardiac function and volume sta-
tus, resulting in an episode of acute decompensation.44 
However, a large number of decompensation cases (up 
to 34%) occur in the absence of identifiable precipitat-
ing factors.45,46 Outcomes after hospitalization for de-
Fig. 2  Right ventricular dysfunction in congestive heart failure. 
Group 4 = depressed right ventricular ejection fraction (RVEF) 
and elevated pulmonary arterial pressure (PAP). Group 1 = pre-
served RVEF and normal PAP. Groups 2 and 3 = at least one fac-
tor (RVEF or PAP) is impaired. (Reprinted with permission from 
Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, 
et al. Independent and additive prognostic value of right ventric-
ular systolic function and pulmonary artery pressure in patients 
with chronic heart failure. J Am Coll Cardiol 2001;37[1]:183-8.)
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compensation are poor: mortality rates are 37% for men 
and 30% for women after 1 year of follow-up.47 Rates of 
rehospitalization range from approximately 30% within 
60 days after discharge45 to 44% at 6 months.48
 The period between symptom onset and hospitaliza-
tion is usually characterized by a gradual deterioration, 
which may be as short as 3 days among elderly patients49 
or as long as 2 weeks among younger patients.50 This pe-
riod could provide an important “window” for moni-
toring values that are predictive of decompensation, and 
the development of mechanical devices that are capable 
of such monitoring could lead to improved outcomes. 
Noninvasive impedance cardiography uses changes in 
thoracic electrical impedance to measure thoracic fluid 
content,51 and studies have shown that this technolo-
gy is effective in predicting the increased near-term 
(14-day) risk of recurrent decompensation, impend-
ing hospitalization, or SCD.52 OptiVol (Medtronic, 
Inc.; Minneapolis, Minn), a system used in conjunction 
with biventricular pacemakers, monitors thoracic im-
pedance through pacemaker electrodes; it is currently 
being tested in clinical trials (MiD-HeFT and FAST). 
The HeartPOD can be percutaneously implanted in-
side the left atrium, where it directly measures left atrial 
pressures and can monitor impending decompensation 
as signaled by rapid increases in pulmonary capillary 
wedge pressure and left atrial pressure. It can also pro-
vide information about the appropriate titration of med-
ications until left atrial pressures are optimized.53 The 
device is currently being investigated in a clinical trial 
(homeostasis) that is aimed at showing the efficacy of 
frequent-dose titration on the basis of left atrial pres-
sure variation.
 Low body temperature is a novel indicator of poor 
prognosis in CHF patients. Our team has shown that 
low body temperature is a univariate predictor of in-
hospital death in patients with decompensation.54 The 
prognostic role of body temperature in predicting death 
in CHF patients has been published elsewhere.48 Exten-
sive work is now being done to identify the predictive 
role of low body temperature in various clinical settings. 
Data have shown that CHF patients who experience a 
decrease in body temperature over time require rehos-
pitalization.55 On the basis of existing data and ongoing 
work, body-temperature monitoring may gain accep-
tance as an inexpensive but sensitive method for device-
based monitoring in CHF patients.
 The Chronicle (Medtronic) is an implantable de-
vice that is programmed to measure right ventricular 
pressures and to estimate pulmonary artery diastol-
ic pressure through a lead implanted in the right ven-
tricular outflow tract.56 Results from initial studies are 
encouraging.57 Right ventricular hemodynamic moni-
toring with Chronicle modestly reduced CHF-related 
events by 22% (P=NS). A subset of CHF patients with 
NYHA functional class III symptoms benefited most 
from Chronicle, with a 41% reduction in CHF-relat-
ed events (P <0.05).58
 Acute decompensation in CHF is a life-threaten-
ing condition. Although our ability to predict future 
decompensation in patients is limited, the use of some 
mechanical devices for measuring certain physiologic 
variables may prove invaluable for predicting which pa-
tients are most at risk in the near-term.
Sudden Cardiac Death
Sudden cardiac death accounts for 300,000 to 400,000 
deaths in the United States each year.59 A large number 
of deaths in CHF patients can be attributed to SCD (al-
most 30% in dilated cardiomyopathy).60 In a study of 
more than 3,000 consecutive patients who underwent 
cardiopulmonary resuscitation for SCD, the survival 
rate was 1.4% until hospital discharge.61 In addition, up 
to 80% of SCD survivors may have anoxic encephal-
opathy.
 The advent of implantable cardioverter-defibrillators 
(ICDs) has had a beneficial effect on outcomes. Several 
clinical trials have shown improved freedom from all-
cause mortality after ICD implantation.62 In the Mul-
ticenter Automatic Defibrillator Implantation Trial 
(MADIT), there was a 56% reduction in death among 
patients who had an ICD.63
 Two noninvasive electrocardiographic tools are being 
used clinically for identifying patients at risk of SCD: 
signal-averaged electrocardiography and T-wave alter-
nans (Fig. 3).64
 One measurable mechanism for possible device-based 
monitoring is a reduction in heart rate variability, in 
response to alterations in autonomic tone. Heart rate 
variability is studied by time-domain or frequency- 
Fig. 3  Significantly elevated T-wave alternans ratios in patients 
susceptible to inducible ventricular arrhythmias. (Reprinted with 
permission from Rosenbaum DS, Jackson LE, Smith JM, Garan 
H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to 
ventricular arrhythmias. N Engl J Med 1994;330[4]:235-41.) 
 
OHD = organic heart disease; EP Test = electrophysiologic 
stimulation of arrhythmias
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domain analysis. Vagal tone on the heart can be mea-
sured by indices of heart rate variability that are derived 
by frequency-domain analysis—that is, low-frequency 
and high-frequency power domains. The frequency do-
mains may then be used in the diagnosis of reduced 
vagal tone or increased sympathetic tone on the heart, 
both of which are arrhythmogenic disorders.65 Heart 
rate variability must be considered with the absolute val-
ues of both low and high frequency to determine what 
factor contributes to the autonomic misbalance and po-
tential arrhythmogenesis.
Conclusions
Despite advances in the management of CHF patients, 
clinical practice still lacks the monitoring and diagnos-
tic methods that have substantial specificity and sensi-
tivity: for example, acute decompensated heart failure 
is still diagnosed by physical examination. Optimal 
management of CHF would reduce death and morbid-
ity, but such management requires close monitoring of 
CHF patients, with the objective of preventing the con-
ditions known to affect outcomes adversely. The de-
velopment of devices designed to predict complications 
by measuring the subtle pathophysiologic processes in-
volved in CHF may provide the foundation for future 
monitoring and diagnostic methods.
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